clinical trial · NCT07802704
A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]
Neoplasms, ProstateRisvutatug rezetecan (Ris-Rez)EnzalutamideAbirateronePrednisonePrednisolone
brief summary
This study aims to evaluate how well risvutatug rezetecan (Ris-Rez) works in treating prostate cancer compared to best supportive/standard of care (BSC) which may include a hormone therapy with an androgen receptor pathway inhibitors (ARPI), by checking whether it makes cancers smaller or disappear completely, if it helps participants live longer, and/or feel better. The study is also assessing whether Ris-Rez is safe and tolerated well by participants and aims to provide a better understanding of the side effects of the drug.
started
Sep 1, 2026
primary completion
Dec 5, 2029
completion
Dec 5, 2029
last updated
Oct 2, 2026
official title
A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of Risvutatug Rezetecan, a B7-H3 Antibody Drug Conjugate (ADC) in Participants With Metastatic Castration-resistant Prostate Cancer (EMBOLD Prostate-302)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol